Read more
Informationen zum Autor DANIEL LEDNICER, PHD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute. Klappentext THE CLASSIC REFERENCE ON THE SYNTHESIS OF MEDICINAL AGENTS --NOW COMPLETELY UPDATED The seventh volume in the definitive series that provides a quick yet thorough overview of the synthetic routes used to access specific classes of therapeutic agents, this volume covers approximately 220 new non-proprietary drug entities introduced since the publication of Volume 6. Many of these compounds represent novel structural types first identified by sophisticated new cell-based assays. Specifically, a significant number of new antineoplastic and antiviral agents are covered. As in the previous volumes, materials are organized by chemical class and syntheses originate with available starting materials. Organized to make the information accessible, this resource covers disease state, rationale for method of drug therapy, and the biological activities of each compound and preparation. The Organic Chemistry of Drug Synthesis, Volume 7 is a hands-on reference for medicinal and organic chemists, and a great resource for graduate and advanced undergraduate students in organic and medicinal chemistry. Zusammenfassung The Organic Chemistry of Drug Synthesis! Volume 7 focuses on the synthetic aspects of the pharmaceutical industry. The synthetic routes and strategies devised to prepare a pharmaceutically active agent are discussed in detail! utilizing common current drugs as examples. Inhaltsverzeichnis Preface xi 1 Open-Chain Compounds 1 1. Peptidomimetic Compounds 2 A. Antiviral Protease Inhibitors 2 1. Human Immunodeficiency Virus 2 2. Human Rhinovirus 9 2. Miscellaneous Peptidomimetic Compounds 11 References 19 2 Alicyclic Compounds 21 1. Monocyclic Compounds 21 A. Prostaglandins 21 B. Antiviral Agents 25 C. Miscellaneous Monocyclic Compounds 29 2. Polycyclic Compounds: Steroids 31 A. 19-Nor Steroids 31 B. Corticosteroid Related Compounds 34 3. Polycyclic Compounds 38 References 40 3 Monocyclic Aromatic Compounds 43 1. Arylcarbonyl Derivatives 43 2. Biphenyls 47 3. Compounds Related to Aniline 50 4. Compounds Related to Arylsulfonic Acids 53 5. Diarylmethanes 58 6. Miscellaneous Monocyclic Aromatic Compounds 60 References 67 4 Carbocyclic Compounds Fused to a Benzene Ring 69 1. Indenes 69 2. Naphthalenes 73 3. Tetrahydronaphthalenes 74 4. Other benzofused carbocyclic compounds 79 References 81 5 Five-Membered Heterocycles 83 1. Compounds with One Heteroatom 83 2. Compounds with Two Heteroatoms 91 A. Oxazole and Isoxazoles 91 B. Imidazoles and a Pyrrazole 94 C. Thiazoles 99 D. Triazoles 103 E. Tetrazoles 109 References 112 6 Six-Membered Heterocycles 115 1. Compounds with One Heteroatom 115 A. Pyridines 115 B. Reduced Pyridines 117 C. Miscellaneous 119 2. Compounds with Two Heteroatoms 121 A. Pyrimidines 121 B. Miscellaneous Six-Membered Heterocycles 133 References 136 7 Five-Membered Heterocycles Fused to One Benzene Ring 139 1. Compounds with One Heteroatom 139 A. Benzo...
